Treatment of Bacterial Vaginosis
For non-pregnant women with bacterial vaginosis, treat with metronidazole 500 mg orally twice daily for 7 days as first-line therapy, which provides superior efficacy compared to alternative regimens. 1
Standard Treatment Regimens
The CDC guidelines establish three recommended first-line options, though they are not equally effective 1:
Recommended regimens (in order of efficacy):
- Metronidazole 500 mg orally twice daily for 7 days (most efficacious)
- Metronidazole gel 0.75%, one full applicator (5g) intravaginally once daily for 5 days
- Clindamycin cream 2%, one full applicator (5g) intravaginally at bedtime for 7 days (least efficacious of the three)
Important caveat: The vaginal clindamycin cream is explicitly noted to be less efficacious than the metronidazole regimens 1. The oral metronidazole regimen should be your default choice.
Alternative regimens (lower efficacy):
- Metronidazole 2g orally as single dose (84% cure rate vs 95% for 7-day regimen) 2
- Clindamycin 300 mg orally twice daily for 7 days
- Clindamycin ovules 100g intravaginally once at bedtime for 3 days
Critical Patient Counseling
Alcohol avoidance: Patients must avoid alcohol during metronidazole treatment and for 24 hours after completion 1
Barrier method warning: Clindamycin cream and ovules are oil-based and weaken latex condoms and diaphragms 1
Special Populations
Pregnancy
All symptomatic pregnant women must be tested and treated due to associations with premature rupture of membranes, chorioamnionitis, preterm labor, preterm birth, postpartum endometritis, and post-cesarean wound infection 1
Recommended regimen for pregnancy:
- Metronidazole 250 mg orally three times daily for 7 days 1
- Alternative: Clindamycin 300 mg orally twice daily for 7 days
Critical distinction: Systemic therapy is preferred over topical agents in pregnancy. Evidence from three trials shows increased adverse events (prematurity and neonatal infections) after clindamycin cream use in pregnancy 1. Multiple studies and meta-analyses have not demonstrated teratogenic or mutagenic effects from metronidazole use during pregnancy 1, 3.
High-risk pregnant women (those with prior preterm delivery) should be screened and treated in early second trimester, as treatment has reduced preterm delivery in three of four randomized controlled trials 1
Metronidazole Allergy or Intolerance
Use clindamycin cream or oral clindamycin as preferred alternatives 1. Metronidazole gel can be considered for patients who don't tolerate systemic metronidazole, but patients allergic to oral metronidazole should NOT receive metronidazole vaginally 1
Management Approach
Follow-up
Follow-up visits are unnecessary if symptoms resolve 1. Recurrence is common—advise patients to return if symptoms recur and use another recommended regimen for recurrent disease 1
Partner Treatment
Do NOT routinely treat sex partners. Clinical trials demonstrate that partner treatment does not affect the woman's response to therapy or likelihood of relapse/recurrence 1, 3. However, note that very recent evidence (2026) suggests partner treatment may reduce recurrence in heterosexual relationships 4, 5, though this contradicts established CDC guidelines.
Recurrent BV
For recurrent disease, extended metronidazole treatment (500 mg twice daily for 10-14 days) is recommended; if ineffective, use metronidazole vaginal gel 0.75% for 10 days followed by twice weekly for 3-6 months 6. No long-term maintenance regimen is officially recommended in guidelines 1
Pre-procedural Considerations
Before surgical abortion or hysterectomy, screen and treat women with BV in addition to routine prophylaxis, as treatment with metronidazole substantially reduces post-abortion PID and post-operative infectious complications (10-75% reduction) 1
Common Pitfalls
- Don't use single-dose metronidazole 2g as first-line—it has significantly lower efficacy (84% vs 95%) 2
- Don't assume all recommended regimens are equal—clindamycin cream is less effective than metronidazole options 1
- Don't use topical clindamycin in pregnancy—associated with adverse neonatal outcomes 1
- Don't treat partners routinely per current guidelines 1
- Don't use probiotics or douching—no data support their use for BV treatment 1